More Positive Lybalvi Data; FDA Wants Non-Opioid Pain Options; ASMR for Anxiety

— News and commentary from the psychiatry world

MedicalToday
Illustration of a brain shaped maze.

Compared with olanzapine alone, combination olanzapine and samidorphan (Lybalvi) treatment resulted in significantly less weight gain in the , Alkermes announced. The once-daily, oral atypical antipsychotic drug was FDA approved in June 2021.

Women who used a computer-based chatbot program that simulated a human conversation were in the following months, according to a new randomized trial. (International Journal of Eating Disorders)

The FDA issued draft guidance containing industry recommendations for developing lasting up to 30 days -- usually reacting to some tissue injury from trauma or surgery -- in support of the HHS Overdose Prevention Strategy.

In a state-specific analysis of in the U.S., researchers found differences in these death rates carried according to differences in social factors, like inequity, isolation, demographics, and healthcare access. (JAMA Network Open)

Autonomous sensory meridian response -- -- seemed to be enjoyed more by people with higher levels of both anxiety and neuroticism. "ASMR may be a suitable psychological intervention for anxious individuals in general," researchers reported in PLOS One.

The U.S. filed a lawsuit against an Alabama-based psychiatrist, alleging that the (dextromethorphan/quinidine) to nursing home residents and in return for kickbacks.

The was the recipient of a $55 million donation, to be used for depression research. (ABC News)

In a 5-year mirror imaging study, people with schizophrenia who were (Invega Sustenna) but were then switched to 3-monthly paliperidone (Invega Trinza) within 18 months had very low rates of rehospitalization. The 6-month paliperidone palmitate option (Invega Hafyera) was recently approved in September 2021. (Journal of Psychiatric Research)

  • author['full_name']

    Kristen Monaco is a senior staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she’s worked at the company since 2015.